MarketCap
Facebook
X
TelegramQuarterly report 2025-Q3
added 11-12-2025
Sintx Technologies Cost of Revenue 2011-2026 | SINT
Cost of Revenue is a financial metric that reflects all direct costs associated with the production of goods or the provision of services that directly led to revenue during the reporting period. It is the total amount of expenses incurred by the company to deliver its products or services, including both production costs and related expenses necessary for delivery or customer support.What is included in the cost of revenue
| Cost Category | Examples |
|---|---|
| Production Costs | Materials, wages of production staff, depreciation of equipment |
| Service and Support | Customer service, user support, technical assistance |
| Delivery and Logistics | Packaging, delivery of goods to customers |
| Hosting and Infrastructure | Servers, cloud platforms (especially for IT and SaaS companies) |
| Content and Licenses | License purchases, production royalties (e.g., in streaming services) |
Importance of the Metric
- Helps to understand how costly the revenue-generating process is.
- A high cost of revenue may indicate:
Poor cost control
Low operational efficiency - A low cost of revenue combined with high revenue indicates high profitability and business competitiveness.
Annual Cost of Revenue Sintx Technologies
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 784 K | 265 K | 449 K | 475 K | 551 K | 56 K | 6.35 M | 3.78 M | 6.25 M | 7.91 M | 7.04 M | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 7.91 M | 56 K | 3.08 M |
Quarterly Cost of Revenue Sintx Technologies
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 115 K | 94 K | 246 K | - | 210 K | 224 K | 223 K | - | 117 K | 104 K | 118 K | - | 89 K | 66 K | 80 K | - | 190 K | 73 K | 61 K | - | 53 K | 163 K | 166 K | - | 151 K | 133 K | 79 K | - | - | 521 K | 524 K | - | 1.41 M | 722 K | 661 K | - | 765 K | 1.02 M | 893 K | - | 1.64 M | 1.36 M | 1.52 M | - | 1.94 M | 1.6 M | 1.65 M | - | 1.74 M | 1.33 M | 1.95 M | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 1.95 M | 53 K | 631 K |
Cost of Revenue of other stocks in the Medical devices industry
| Issuer | Cost of Revenue | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Abiomed
ABMD
|
162 M | - | - | $ 17.2 B |  USA |
 |
Acutus Medical
AFIB
|
10.3 M | - | -26.83 % | $ 2.62 M | USA |
 |
Allied Healthcare Products
AHPI
|
24.5 M | - | 3.58 % | $ 2.21 M | USA |
 |
Apollo Endosurgery
APEN
|
34.4 M | - | - | $ 475 M | USA |
 |
Axonics Modulation Technologies
AXNX
|
76 M | - | - | $ 3.31 B | USA |
 |
AxoGen
AXGN
|
45.4 M | $ 31.85 | 2.68 % | $ 1.41 B | USA |
 |
Cognyte Software Ltd.
CGNT
|
104 M | $ 8.97 | -1.59 % | $ 644 M |  Israel |
 |
BIOLASE
BIOL
|
32.4 M | - | -13.19 % | $ 166 K | USA |
 |
BioSig Technologies
BSGM
|
57 K | - | 37.08 % | $ 85.7 M | USA |
 |
Apyx Medical Corporation
APYX
|
18.6 M | $ 3.89 | -2.51 % | $ 135 M | USA |
 |
Alphatec Holdings
ATEC
|
187 M | $ 16.95 | -4.48 % | $ 2.42 B | USA |
 |
Bio-Rad Laboratories
BIO
|
1.19 B | $ 312.8 | -0.23 % | $ 8.83 B | USA |
 |
CONMED Corporation
CNMD
|
574 M | $ 41.19 | -0.91 % | $ 1.27 B | USA |
 |
EDAP TMS S.A.
EDAP
|
37.6 M | $ 3.69 | -9.12 % | $ 138 M |  France |
 |
Bruker Corporation
BRKR
|
1.72 B | $ 50.26 | 3.85 % | $ 7.49 K | USA |
 |
Boston Scientific Corporation
BSX
|
5.26 B | $ 91.09 | 3.43 % | $ 134 B | USA |
 |
Conformis
CFMS
|
38.8 M | - | - | $ 16.4 M | USA |
 |
Abbott Laboratories
ABT
|
18.7 B | $ 121.01 | -0.61 % | $ 211 B | USA |
 |
Cardiovascular Systems
CSII
|
63.4 M | - | 0.15 % | $ 844 M | USA |
 |
Cutera
CUTR
|
171 M | - | -10.19 % | $ 1.99 M | USA |
 |
Dynatronics Corporation
DYNT
|
21.4 M | - | 14.99 % | $ 929 K | USA |
 |
Neovasc
NVCN
|
556 K | - | - | $ 111 M |  Canada |
 |
GBS
GBS
|
1.81 M | - | -0.57 % | $ 7.12 M | USA |
 |
InMode Ltd.
INMD
|
77.8 M | $ 13.79 | -1.11 % | $ 1.09 B | Israel |
 |
Eargo
EAR
|
23 M | - | - | $ 10.2 M | USA |
 |
Electromed
ELMD
|
14 M | $ 27.84 | 0.04 % | $ 235 M | USA |
 |
Second Sight Medical Products
EYES
|
11.8 M | - | -0.97 % | $ 54.4 M | USA |
 |
Align Technology
ALGN
|
1.2 B | $ 165.75 | -3.35 % | $ 12.4 B | USA |
 |
Accuray Incorporated
ARAY
|
312 M | $ 0.81 | -3.78 % | $ 83.2 M | USA |
 |
Avinger
AVGR
|
5.65 M | - | -20.74 % | $ 369 K | USA |
 |
ClearPoint Neuro
CLPT
|
12.3 M | $ 13.82 | -5.67 % | $ 374 M | USA |
 |
IRadimed Corporation
IRMD
|
16.9 M | $ 102.68 | 0.67 % | $ 1.3 B | USA |
 |
Integer Holdings Corporation
ITGR
|
1.26 B | $ 84.87 | -1.06 % | $ 2.85 B | USA |
 |
Invacare Corporation
IVC
|
566 M | - | - | $ 24.7 M | USA |
 |
LivaNova PLC
LIVN
|
383 M | $ 62.45 | 0.55 % | $ 3.39 B |  Britain |
 |
Globus Medical
GMED
|
1.04 B | $ 92.68 | -0.85 % | $ 12.6 B | USA |
 |
Integra LifeSciences Holdings Corporation
IART
|
728 M | $ 11.98 | -3.51 % | $ 923 M | USA |
 |
Aziyo Biologics
AZYO
|
13.7 M | - | 1.37 % | $ 20.5 M | USA |
 |
Pulmonx Corporation
LUNG
|
21.8 M | $ 1.78 | 0.28 % | $ 69.6 M | USA |